Tri Locum Partners’s ACELYRIN SLRN Stock Holding History

Tri Locum Partners’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-155,573	Closed	-$1.58M	–	52
2023 Q3	$1.58M	Buy	+155,573	New	+$3.3M	0.51%	34

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tri Locum Partners's SLRN Position: Q4 2023 in Review

Tri Locum Partners sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 155,573 shares — an estimated $1.58M sold.

Tri Locum Partners first reported a position in SLRN in Q3 2023 and held it in 1 quarter. The position peaked at $1.58M in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Tri Locum Partners reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Tri Locum Partners sold 155,573 ACELYRIN shares in Q4 2023, an estimated $1.58M.
Tri Locum Partners first reported a position in ACELYRIN in Q3 2023 and held it in 1 quarter.
Tri Locum Partners's ACELYRIN position peaked at $1.58M in Q3 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.